Analytical aspects of the implementation of biomarkers in clinical transplantation

• Verfasst von: Shipkova, Maria [VerfasserIn]
• Verfasst von: Sommerer, Claudia [VerfasserIn]
• Titel: Analytical aspects of the implementation of biomarkers in clinical transplantation
• Verf.angabe: Shipkova, Maria MD, López, Olga Millán PhD, Picard, Nicolas PharmD, PhD, Noceti, Ofelia PharmD, PhD, Sommerer, Claudia MD, Christians, Uwe MD, PhD, Wieland, Eberhard MD
• E-Jahr: 2016
• Jahr: April 2016
• Umfang: 13 S.
• Fussnoten: Gesehen am 06.05.2020
• Titel Quelle: Enthalten in: Therapeutic drug monitoring
• Ort Quelle: Philadelphia, Pa. : Lippincott Williams & Wilkins, 1979
• Jahr Quelle: 2016
• Band/Heft Quelle: 38(2016), Seite S80-S92
• ISSN Quelle: 1536-3694
• DOI: doi:10.1097/FTD.0000000000000230
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1697313876

Abstract

In response to the urgent need for new reliable biomarkers to complement the guidance of the immunosuppressive therapy, a huge number of biomarker candidates to be implemented in clinical practice have been introduced to the transplant community. This includes a diverse range of molecules with very different molecular weights, chemical and physical properties, ex vivo stabilities, in vivo kinetic behaviors, and levels of similarity to other molecules, etc. In addition, a large body of different analytical techniques and assay protocols can be used to measure biomarkers. Sometimes, a complex software-based data evaluation is a prerequisite for appropriate interpretation of the results and for their reporting. Although some analytical procedures are of great value for research purposes, they may be too complex for implementation in a clinical setting. Whereas the proof of “fitness for purpose” is appropriate for validation of biomarker assays used in exploratory drug development studies, a higher level of analytical validation must be achieved and eventually advanced analytical performance might be necessary before diagnostic application in transplantation medicine. A high level of consistency of results between laboratories and between methods (if applicable) should be obtained and maintained to make biomarkers effective instruments in support of therapeutic decisions. This overview focuses on preanalytical and analytical aspects to be considered for the implementation of new biomarkers for adjusting immunosuppression in a clinical setting and highlights critical points to be addressed on the way to make them suitable as diagnostic tools. These include but are not limited to appropriate method validation, standardization, education, automation, and commercialization.